Sally Church

216 posts · 263,738 views

Sort by Latest Post, Most Popular

View by Condensed, Full

  • February 7, 2014
  • 10:24 AM

Developing a predictive biomarker for PARP inhibition

by Sally Church in Pharma Strategy Blog

Today’s Science Friday post looks at the identification of a potential new biomarker and possible strategies for expanding use of…

... Read more »

  • January 31, 2014
  • 12:38 PM

Update on RAF resistance in metastatic melanoma

by Sally Church in Pharma Strategy Blog

“RAF inhibitors (vemurafenib and dabrafenib) have profound clinical activity in patients with BRAF-mutant melanoma, but their therapeutic effects are limited…

... Read more »

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB.... (2014) Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer discovery, 4(1), 80-93. PMID: 24265155  

Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV.... (2014) The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer discovery, 4(1), 94-109. PMID: 24265153  

Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN.... (2014) MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition. Cancer discovery, 4(1), 61-8. PMID: 24265154  

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, & Stuart DD. (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 494(7436), 251-5. PMID: 23302800  

  • January 17, 2014
  • 02:09 PM

Will intermittent dosing transform TKI therapy in cancer research?

by Sally Church in Pharma Strategy Blog

At AACR last year, one of the most revealing presentations was on metastatic melanoma, specifically, some elegant research by Meghna…

... Read more »

Marie Will, Alice Can Ran Qin, Weiyi Toy, Zhan Yao, Vanessa Rodrik-Outmezguine, Claudia Schneider, Xiaodong Huang, Prashant Monian, Xuejun Jiang, Elisa de Stanchina.... (2014) Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discovery. info:/10.1158/2159-8290.CD-13-0611

  • October 16, 2013
  • 11:47 AM

Removing the PD-1 brake enhances the effect on adoptive CAR T cells

by Sally Church in Pharma Strategy Blog

Someone in my Twitter stream kindly shared a link to an article this morning on how removing the PD-1 brake…

... Read more »

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, & Darcy PK. (2013) Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. PMID: 23873688  

Morales-Kastresana A, Labiano S, Quetglas JI, & Melero I. (2013) Better Performance of CARs Deprived of the PD-1 Brake. Clinical cancer research : an official journal of the American Association for Cancer Research. PMID: 24004672  

  • September 19, 2013
  • 12:07 PM

Update on KRAS and NRAS mutations in colorectal cancer

by Sally Church in Pharma Strategy Blog

A new NEJM article on KRAS and metastatic colorectal cancer (CRC) caught my eye last week. One of the challenges…

... Read more »

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J.... (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England journal of medicine, 369(11), 1023-34. PMID: 24024839  

  • July 30, 2013
  • 07:36 AM

Transformative antibody technology in cancer research

by Sally Church in Pharma Strategy Blog

Recently, I came across an exciting new development in a Nature publication and couldn’t resist teasing my Twitter followers with…

... Read more »

  • March 11, 2013
  • 01:49 PM

Bromodomain Inhibitors – an exciting new target in cancer research?

by Sally Church in Pharma Strategy Blog

One of the interesting things about basic cancer research is that new targets emerge all the time, offering fresh opportunities…

... Read more »

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W., Fedorov, O., Morse, E., Keates, T., Hickman, T., Felletar, I.... (2010) Selective inhibition of BET bromodomains. Nature, 468(7327), 1067-1073. DOI: 10.1038/nature09504  

Puissant, A., Frumm, S., Alexe, G., Bassil, C., Qi, J., Chanthery, Y., Nekritz, E., Zeid, R., Gustafson, W., Greninger, P.... (2013) Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 3(3), 308-323. DOI: 10.1158/2159-8290.CD-12-0418  

Lin, C., Lovén, J., Rahl, P., Paranal, R., Burge, C., Bradner, J., Lee, T., & Young, R. (2012) Transcriptional Amplification in Tumor Cells with Elevated c-Myc. Cell, 151(1), 56-67. DOI: 10.1016/j.cell.2012.08.026  

Mertz, J., Conery, A., Bryant, B., Sandy, P., Balasubramanian, S., Mele, D., Bergeron, L., & Sims, R. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences, 108(40), 16669-16674. DOI: 10.1073/pnas.1108190108  

  • March 1, 2013
  • 09:50 AM

ASH 2012 update on ARRY-520 in multiple myeloma

by Sally Church in Pharma Strategy Blog

After highlighting the interesting biomarker program associated with AVEO’s tivozanib in renal cell and triple negative breast cancers in the last…

... Read more »

  • November 29, 2012
  • 10:26 AM

Effectively targeting KRAS in lung cancer with a MEK inhibitor

by Sally Church in Pharma Strategy Blog

Today is the 1000th blog post here on PSB, a milestone I never imagined actually reaching while writing the inaugural…

... Read more »

  • April 23, 2012
  • 12:00 PM

Highlights of AACR 2012 – Part 3

by Sally Church in Pharma Strategy Blog

Aside from the already published Part 1 and Part 2 blog posts about AACR here on PSB, you can also find some more coverage, including summaries of other topics, on the companion Biotech Strategy Blog, such as the following: SARDs, … Continue reading →

... Read more »

  • March 23, 2012
  • 12:51 PM

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer

by Sally Church in Pharma Strategy Blog

One of the biggest challenges facing cancer research was aptly summarised by Levi Garraway and Pasi Jänne in this month’s Cancer Discovery journal: “All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding … Continue reading →
... Read more »

Doebele, R., Pilling, A., Aisner, D., Kutateladze, T., Le, A., Weickhardt, A., Kondo, K., Linderman, D., Heasley, L., Franklin, W.... (2012) Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research, 18(5), 1472-1482. DOI: 10.1158/1078-0432.CCR-11-2906  

Katayama, R., Shaw, A., Khan, T., Mino-Kenudson, M., Solomon, B., Halmos, B., Jessop, N., Wain, J., Yeo, A., Benes, C.... (2012) Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine, 4(120), 120-120. DOI: 10.1126/scitranslmed.3003316  

  • March 6, 2012
  • 09:10 AM

The importance of metabolism in cancer research

by Sally Church in Pharma Strategy Blog

Cancer metabolism is fast becoming an area to watch out for in R&D.  Last month I tweeted that I was attending a one day meeting at NY Academy of Sciences on Cancer Metabolism with keynote speakers Drs Lou Cantley and … Continue reading →
... Read more »

Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB.... (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proceedings of the National Academy of Sciences of the United States of America, 105(48), 18782-7. PMID: 19033189  

Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H.... (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature genetics, 43(9), 869-74. PMID: 21804546  

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC.... (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462(7274), 739-44. PMID: 19935646  

  • March 5, 2012
  • 10:55 AM

nab-Paclitaxel and its potential role in pancreatic cancer

by Sally Church in Pharma Strategy Blog

Back in 2009 at the American Association for Cancer Research (AACR) Molecular Targets meeting, a researcher (Anirban Maitra) from Boston had a most interesting poster about the use of nanotechnology to deliver nab-paclitaxel (Abraxane) to pancreatic adenocarcinomas in a more … Continue reading →
... Read more »

  • February 26, 2012
  • 04:42 AM

Will combining custirsen and MDV3100 reduce resistance in advanced prostate cancer?

by Sally Church in Pharma Strategy Blog

Greetings from the European Association of Urology (EAU) congress in Paris. Despite the grey drizzle typical of Europe in winter, this is actually quite an interesting meeting with lots of poster presentations. One poster that caught my eye yesterday was … Continue reading →
... Read more »

  • February 24, 2012
  • 10:10 AM

Combined VEGF and MET inhibition in some cancers may be better than either alone

by Sally Church in Pharma Strategy Blog

A couple of recent controversies in the field of angiogenesis have fascinated scientists and clinicians alike, namely: Does VEGF inhibition lead to more aggressive tumours? What drives metastases and invasion? What is the role of tumour hypoxia in this process? … Continue reading →
... Read more »

  • February 15, 2012
  • 05:10 PM

Raised platelets reduce survival in ovarian cancer

by Sally Church in Pharma Strategy Blog

During my years in Pharmaland, I often sat in waiting rooms waiting to see the Principal Investigator (PI) for one of the studies we were doing.  I would generally see them at the end of the clinic, preferring to arrive … Continue reading →
... Read more »

Stone, R., Nick, A., McNeish, I., Balkwill, F., Han, H., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G., Pecot, C., Coward, J.... (2012) Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 366(7), 610-618. DOI: 10.1056/NEJMoa1110352  

Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J.... (2011) Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 17(18), 6083-6096. DOI: 10.1158/1078-0432.CCR-11-0945  

  • February 14, 2012
  • 09:09 AM

A new fusion gene target in a rare soft tissue sarcoma

by Sally Church in Pharma Strategy Blog

Every now and then my eye is caught by reports of new fusion genes being found in different cancers.  Often these descriptions involve researchers across multiple laboratories due to the rarity of the target.  Following a discussion on Twitter yesterday, … Continue reading →
... Read more »

Tanas, M., Sboner, A., Oliveira, A., Erickson-Johnson, M., Hespelt, J., Hanwright, P., Flanagan, J., Luo, Y., Fenwick, K., Natrajan, R.... (2011) Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma. Science Translational Medicine, 3(98), 98-98. DOI: 10.1126/scitranslmed.3002409  

  • February 10, 2012
  • 04:24 PM

The role of the Androgen Receptor in breast cancer

by Sally Church in Pharma Strategy Blog

This week I have been in Orlando for the American Association for Cancer Research (AACR) Special Conference on prostate cancer chaired by Drs Arul Chinnaiyan (U. of Michigan) and Charles Sawyers (MSKCC).  It was a superb meeting, probably one of … Continue reading →
... Read more »

Hu, R., Dawood, S., Holmes, M., Collins, L., Schnitt, S., Cole, K., Marotti, J., Hankinson, S., Colditz, G., & Tamimi, R. (2011) Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women. Clinical Cancer Research, 17(7), 1867-1874. DOI: 10.1158/1078-0432.CCR-10-2021  

  • February 2, 2012
  • 11:39 AM

Is ARN-509 (Aragon) potentially better than MDV-3100 (Medivation) in advanced prostate cancer?

by Sally Church in Pharma Strategy Blog

Many readers will have noticed that the advanced prostate cancer market is rapidly becoming crowded with three new therapies (cabazitaxel, sipuleucel-T and abiraterone) already approved and several more in late stage development, including Alpharadin (radium-223) and MDV3100, both likely to … Continue reading →
... Read more »

  • January 31, 2012
  • 06:09 PM

Update on Medivation’s MDV3100 in advanced prostate cancer

by Sally Church in Pharma Strategy Blog

This weekend heralds the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) meeting in San Francisco, although ASCO held their press briefing today to provide an update on some of the key topics. For those of you interested in … Continue reading →
... Read more »

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, & Sawyers CL. (2004) Molecular determinants of resistance to antiandrogen therapy. Nature medicine, 10(1), 33-9. PMID: 14702632  

Carver, B., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V., Le, C., Koutcher, J., Scher, H.... (2011) Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 19(5), 575-586. DOI: 10.1016/j.ccr.2011.04.008  

join us!

Do you write about peer-reviewed research in your blog? Use to make it easy for your readers — and others from around the world — to find your serious posts about academic research.

If you don't have a blog, you can still use our site to learn about fascinating developments in cutting-edge research from around the world.

Register Now

Research Blogging is powered by SRI Technology.

To learn more, visit